Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 3,541 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infant Clear all
Recruiting No phase listed Observational

Motor-voice Assessment in Infants (MAMI)

NCT06807203
View directory record Official record
Conditions
Cerebral Palsy Infantile, Pre-Term, Motor Delay, Neurodevelopmental Disorders, Autism Spectrum Disorder
Interventions
Behavioral observation
Other
Lead sponsor
Ohio State University
Other
Eligibility
Up to 10 Days
Enrollment
46 participants
Timeline
2025 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 23, 2026, 7:04 AM EDT
Completed Not applicable Interventional

NICUSeq: A Trial to Evaluate the Clinical Utility of Human Whole Genome Sequencing (WGS) Compared to Standard of Care in Acute Care Neonates and Infants

NCT03290469
View directory record Official record
Conditions
Rare Diseases
Interventions
clinical whole genome sequencing (cWGS)
Other
Lead sponsor
Illumina, Inc.
Industry
Eligibility
1 Day to 120 Days
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Orange, California • St Louis, Missouri • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 23, 2026, 7:04 AM EDT
Active, not recruiting No phase listed Observational

Ultrasound Assessment of BC in the NICU

NCT03241082
View directory record Official record
Conditions
Premature Infant
Interventions
ultrasound
Device
Lead sponsor
University of Minnesota
Other
Eligibility
25 Weeks to 34 Weeks
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 23, 2026, 7:04 AM EDT
Recruiting Not applicable Interventional

Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

NCT02958462
View directory record Official record
Conditions
Myeloid Malignancy, Inherited Bone Marrow Failure Syndrome, Clonal Expansion, Cytopenia, Bone Marrow Failure Syndrome, Clonal Cytopenia of Undetermined Significance, Clonal Hematopoiesis of Indeterminate Potential, Hematologic Neoplasms, Hematopoietic and Lymphatic System Neoplasm, Hereditary Neoplastic Syndrome, Idiopathic Cytopenia of Undetermined Significance, Idiopathic Dysplasia of Uncertain Significance, Low Risk Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Punch Biopsy, Buccal Swab, Clinical Evaluation, Genetic Counseling, Quality-of-Life Assessment, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2035
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 23, 2026, 7:04 AM EDT
Completed Not applicable Interventional

Cold Liquids Fed to Preterm Infants: Efficacy and Safety After 10 Minutes of Exposure

NCT02935946
View directory record Official record
Conditions
Deglutition Disorders, Respiratory Aspiration
Interventions
Cold Liquid Barium
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
36 Weeks to 43 Weeks
Enrollment
4,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Oct 23, 2026, 7:04 AM EDT
Completed Phase 4 Interventional

Hyperpolarized Imaging for New Treatments

NCT04259970
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Initiation of CFTR Modulator
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 18 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Cincinnati, Ohio • Charlottesville, Virginia • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 7:04 AM EDT
Terminated Not applicable Interventional Results available

Interventions to Help Infants Recover in the Hospital

NCT03881553
View directory record Official record
Conditions
Infant Apnea, Neonatal Abstinence Syndrome, Sleep
Interventions
NEATCAP, SVS mattress
Device
Lead sponsor
Elisabeth Salisbury, PhD
Other
Eligibility
2 Days to 3 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 23, 2026, 7:04 AM EDT
Completed Phase 2 Interventional

Study Of Angiomax In Infants Under Six Months With Thrombosis

NCT00043277
View directory record Official record
Conditions
Thrombosis
Interventions
Angiomax (bivalirudin)
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
0 Years to 6 Months
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2006 · Synced Oct 23, 2026, 7:04 AM EDT
Completed Phase 3 Interventional Results available

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation

NCT00909727
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
17
States / cities
Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Oct 23, 2026, 7:04 AM EDT
Completed Phase 3 Interventional Results available

EZN-2279 in Patients With ADA-SCID

NCT01420627
View directory record Official record
Conditions
ADA-SCID, Adenosine Deaminase Deficiency, Severe Combined Immunodeficiency
Interventions
EZN-2279, Adagen
Biological
Lead sponsor
Leadiant Biosciences, Inc.
Industry
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 23, 2026, 7:04 AM EDT
Completed No phase listed Observational

A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype

NCT01358370
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency, Wolman Disease
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
Los Angeles, California • Palo Alto, California • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 23, 2026, 7:04 AM EDT
Completed Not applicable Interventional

Parent Communication for Feeding an Infant With a Heart Defect

NCT04452201
View directory record Official record
Conditions
Communication, Heart Defects, Congenital, Infant Conditions
Interventions
Guided Participation
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 23, 2026, 7:04 AM EDT
Completed Phase 2Phase 3 Interventional

Dextrose Gel Does Not Prevent Neonatal Hypoglycemia

NCT02523222
View directory record Official record
Conditions
Hypoglycemia, Infant, Small for Gestational Age, Premature Birth of Newborn, Fetal Macrosomia, Intrauterine Growth Restriction, Complication of Prematurity, Neonatal Hypoglycemia
Interventions
40% Dextrose gel
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
0 Hours to 1 Hour
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 23, 2026, 7:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Delayed Cord Clamp and/or Indomethacin on Preterm Infant Brain Injury

NCT02221219
View directory record Official record
Conditions
Intraventricular Hemorrhage, Periventricular Leukomalacia, Brain Injury, Renal Injury
Interventions
Indomethacin, delay in umbilical cord clamp at birth, placebo infusion, immediate cord clamp at birth
Drug · Procedure
Lead sponsor
Hong Huang
Other
Eligibility
24 Weeks to 30 Weeks
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 23, 2026, 7:04 AM EDT
Completed No phase listed Observational

A 24 Month Observational Study of Infants 3-24 Months, Who Suffer an Acute Episode of Respiratory Infection and Wheezing Illness

NCT03741322
View directory record Official record
Conditions
Respiratory Tract Infections, Wheezing
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
3 Months to 24 Months
Enrollment
5 participants
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 23, 2026, 7:04 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

NCT02508207
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Tezacaftor/Ivacaftor, Ivacaftor, Tezacaftor/Ivacaftor matching placebo, Ivacaftor matching placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 23, 2026, 7:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Maternal Obesity and Small for Gestational Age Infants

NCT00371657
View directory record Official record
Conditions
Obesity, Small for Gestational Age
Interventions
Not listed
Lead sponsor
Oklahoma State University Center for Health Sciences
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 4, 2008 · Synced Oct 23, 2026, 7:04 AM EDT
Active, not recruiting No phase listed Observational

Vincristine Pharmacokinetics in Infants

NCT05359237
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Vincristine
Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 12 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 23, 2026, 7:04 AM EDT
Recruiting Phase 1 Interventional

Inhaled Ciclesonide Study in Preterm Infants

NCT06589245
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Alvesco Inhalant Product
Drug
Lead sponsor
Venkatesh Sampath
Other
Eligibility
8 Days to 35 Days
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 7:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multi-center Isoelectric EEG Study in Children Under General Anesthesia

NCT03432351
View directory record Official record
Conditions
Electroencephalography, General Anesthesia, Pediatric Anesthesia
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 36 Months
Enrollment
687 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Cincinnati, Ohio • Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 23, 2026, 7:04 AM EDT
Completed Phase 4 Interventional

Inhaled Nitric Oxide by Oxygen Hood in Neonates

NCT00732537
View directory record Official record
Conditions
Respiratory Failure, Infant, Persistent Fetal Circulation
Interventions
inhaled Nitric Oxide, Oxygen (>90% by hood) - standard therapy
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Hour to 1 Week
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 12, 2008 · Synced Oct 23, 2026, 7:04 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effect of Early Limited Formula on Total Serum Bilirubin Among Newborns With Hyperbilirubinemia

NCT01330667
View directory record Official record
Conditions
Hyperbilirubinemia, Neonatal
Interventions
Nutramigen Infant Formula
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
36 Hours to 96 Hours
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 23, 2026, 7:04 AM EDT
Completed Phase 4 Interventional Results available

A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI

NCT00299000
View directory record Official record
Conditions
Mucopolysaccharidosis VI, Maroteaux-Lamy Syndrome
Interventions
Naglazyme
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Up to 1 Year
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Los Angeles, California • Oakland, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 23, 2026, 7:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

BIG Study (Brain, Immune, and Gut Health Evaluation of Infants/Young Children Fed Infant Formula, and Later Supplemental Toddler Nutrition, With 5 Specific HMOs)

NCT04957992
View directory record Official record
Conditions
Growth
Interventions
Control Infant Formula, Control Toddler Drink, Experimental Infant Formula, Experimental Toddler Drink, Human Milk, Human Milk Supplemental Formula, Human Milk Toddler Drink
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
0 Days to 14 Days
Enrollment
607 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
42
States / cities
Phoenix, Arizona • Glenwood, Arkansas • Hot Springs, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 23, 2026, 7:04 AM EDT